Semaphorins are implicated in glioma progression, although little is known about the underlying mechanisms. We have reported plexin-B3 expression in human gliomas, which upon stimulation by Sema5A causes significant inhibition of cell migration and invasion. The concomitant inactivation of Rac1 is of mechanistic importance because forced expression of constitutively active Rac1 abolishes these inhibitory effects. Furthermore, Sema5A induces prominent cell collapse and ramification of processes reminiscent of astrocytic morphology, which temporally associate with extensive disassembly of actin stress fibers and disruption of focal adhesions, followed by accumulation of actin patches in protrusions. Mechanistically, Sema5A induces transient protein kinase C (PKC) phosphorylation of fascin-1, which can reduce its actin-binding/bundling activities and temporally parallels its translocation from cell body to extending processes. PKC inhibition or fascin-1 knockdown is sufficient to abrogate Sema5A-induced morphological differentiation, whereas the process is hastened by forced expression of fascin-1. Intriguingly, Sema5A induces re-expression of glial fibrillary acidic protein (GFAP), which when silenced restricts differentiation of glioma cells to bipolar instead of multipolar morphology. Therefore, we hypothesize complementary functions of fascin-1 and GFAP in the early and late phases of Sema5A-induced astrocytic differentiation of gliomas, respectively. In summary, Sema5A and plexin-B3 impede motility but promote differentiation of human gliomas. These effects are plausibly compromised in high-grade human astrocytomas in which Sema5A expression is markedly reduced, hence leading to infiltrative and anaplastic characteristics. This is evident by increased invasiveness of glioma cells when endogenous Sema5A is silenced. Therefore, Sema5A and plexin-B3 represent potential novel targets in counteracting glioma progression.
Semaphorins are implicated in glioma progression, although little is known about the underlying mechanisms. We have reported plexin-B3 expression in human gliomas, which upon stimulation by Sema5A causes significant inhibition of cell migration and invasion. The concomitant inactivation of Rac1 is of mechanistic importance because forced expression of constitutively active Rac1 abolishes these inhibitory effects. Furthermore, Sema5A induces prominent cell collapse and ramification of processes reminiscent of astrocytic morphology, which temporally associate with extensive disassembly of actin stress fibers and disruption of focal adhesions, followed by accumulation of actin patches in protrusions. Mechanistically, Sema5A induces transient protein kinase C (PKC) phosphorylation of fascin-1, which can reduce its actin-binding/bundling activities and temporally parallels its translocation from cell body to extending processes. PKC inhibition or fascin-1 knockdown is sufficient to abrogate Sema5A-induced morphological differentiation, whereas the process is hastened by forced expression of fascin-1. Intriguingly, Sema5A induces re-expression of glial fibrillary acidic protein (GFAP), which when silenced restricts differentiation of glioma cells to bipolar instead of multipolar morphology. Therefore, we hypothesize complementary functions of fascin-1 and GFAP in the early and late phases of Sema5A-induced astrocytic differentiation of gliomas, respectively. In summary, Sema5A and plexin-B3 impede motility but promote differentiation of human gliomas.
Introduction
Gliomas represent the most common primary tumors in the central nervous system. They are characterized by rapid proliferation, low differentiation and high invasiveness. Interestingly, clinical observations revealed preferential invasion of glioblastomas along white matter tracts such as the corpus callosum (Bellail et al., 2004) , and cessation of cell migration is often observed at the junction between the white and gray matter. These findings suggest the presence of tropic and guidance cues for the invasion of glioma cells within the central nervous system. Accumulating evidence suggests the axon guidance molecules semaphorins and plexins are involved in cancer progression, invasion and metastasis (Neufeld et al., 2005; Chedotal, 2007) .
Semaphorins, originally identified as guidance cues that navigate axons in the nervous system, fall into eight subclasses of secreted, membrane glycosylphophatidylinositol-anchored and transmembrane proteins. All known semaphorins feature a Sema domain at the N terminus, which is also present in their receptors plexins (Tamagnone et al., 1999) . Among them, class 3 semaphorins are the most thoroughly studied for their role in cancer progression. Members such as Sema3B and Sema3F are implicated as tumor suppressors and display potent anti-tumor effects in breast and lung cancer (Castro-Rivera et al., 2004; Kusy et al., 2005) , whereas Sema3A was shown to inhibit endothelial cell migration and tumor cell invasive growth in vitro (Catalano et al., 2004) . In contrast, Sema3C and Sema3E promote tumorigenesis and tumor progression (Christensen et al., 2005; Banu et al., 2006) . Semaphorins and their receptors neuropilins and plexins have recently been shown to be expressed in various types of gliomas (Correa et al., 2001; Rieger et al., 2003; Rich et al., 2005; Hu et al., 2007; Karayan-Tapon et al., 2008) . However, their functional significance in glioma progression remains to be elucidated.
In addition to soluble class 3 members, membranebound semaphorins of class 4, 5 and 6 are emerging as important factors in cancer development (Woodhouse et al., 2003; Dhanabal et al., 2005; Basile et al., 2006; Sadanandam et al., 2007) . Among them, class 5 semaphorins are peculiar because of the presence of thrombospondin repeats in the extracellular domain, which have been implicated in cancer cell motility and proliferation (Roberts, 1996) . Drosophila Sema5c, for instance, is required for tumorigenicity induced by deletion of the tumor-suppressor gene l(2)gl (Woodhouse et al., 2003) . Although semaphorin 5A (Sema5A) was shown to be associated with the aggressive nature of pancreatic, prostate and gastric cancers by two laboratories (Sadanandam et al., 2007 (Sadanandam et al., , 2010 Pan et al., 2010) , a recent report has demonstrated a downregulation of Sema5A expression in non-small cell lung carcinoma, which is associated with poor survival of patients (Lu et al., 2010) . The Sema5A transcript has formerly been detected in primary astrocytomas (Rickman et al., 2001) . We have recently shown that Sema5A and its receptor plexin-B3 function to suppress glioma cell motility (Li and Lee, 2010) , although its potential contribution to glioma progression remains to be determined. Here, we reported the expression of Sema5A and its receptor plexin-B3 in human gliomas. A significant reduction of Sema5A protein expression was observed towards high-grade astrocytomas.
Stimulating glioma cells with Sema5A imposes inhibitory effects on cell motility, triggers remodeling of the actin cytoskeleton and induces astrocytic differentiation in a plexin-B3-dependent manner. Taken together, these findings support the notion that Sema5A and plexin-B3 function to counteract glioma progression, which is compromised in advanced grades of the cancer.
Results
Sema5A inhibits glioma cell migration and invasion through its receptor plexin-B3 As a first step to understand the functions of plexin-B3 in gliomas, we surveyed its expression in a panel of human glioma cell lines. Reverse transcriptase-PCR analysis showed plexin-B3 expression in all cell lines examined ( Figure 1a ). Western blot analysis of glioma Western blot detection of endogenous plexin-B3 expression in the four human glioma cell lines as a B260-kDa protein using plexin-B3CD antibody. GAPDH serves as a protein loading control. (c) Sema5A inhibits glioma cell migration in a scratch wound assay. Cell migration into the wounded area after 24 h of Sema5A-Fc or Fc treatment was quantified. Cell migration in Sema5A-Fc was expressed as a percentage to that in Fc control as shown in the bar graph. *Po0.05, **Po0.01 vs Fc control. (d) Sema5A inhibits human glioma cell invasion through Matrigel in Transwell assay, as measured by the absorbance of crystal violet stain eluted from the cells. Cell invasion in the Sema5A-Fc group was expressed as a percentage to that in the Fc control. *Po0.05, **Po0.01 vs Fc control. (e) Western blot analysis shows successful downregulation of endogenous plexin-B3 in U87-MG cells by three independent siRNAs (plexin-B3 siRNA-1, siRNA-2 or siRNA-3). siRNA of scrambled sequence and mock transfection serve as controls. Equal loading of protein was confirmed with GAPDH antibody. (f) Sema5A inhibits U87-MG glioma cell invasion through plexin-B3. Invasion of glioma cells transfected with siRNA control or siRNAs against plexin-B3 for 2 days towards Sema5A-Fc or Fc control was similarly measured. Cell invasion under Sema5A-Fc treatment was expressed as the percentage absorbance relative to that in the Fc-treated control. ***Po0.001 vs Fc control.
Sema5A and plexin-B3 in glioma progression X Li et al cell lysates using an antibody against the cytoplasmic domain of plexin-B3 revealed its expression as a 260-kDa protein (Figure 1b ), in agreement with full-length plexin-B3 heterologously expressed in HEK293 cells. Next, we investigated whether endogenous plexin-B3 in gliomas might have any regulatory functions in cell motility upon stimulation by its ligand Sema5A. All four human glioma cells were challenged with Sema5A-Fc or Fc control protein, and cell migration was monitored using a scratch wound assay. Similar to untreated controls, glioma cells treated with the Fc control protein actively migrated to populate the scratch wound within 24 h. However, Sema5A-Fc treatment led to a significant reduction in migration by 30-50% to that in the Fc control ( Figure 1c , Supplementary Figure S1A) . Next, the effect of Sema5A on glioma cell invasion was evaluated by an in vitro transfilter Matrigel invasion assay. Human glioma cells untreated or subjected to the Fc control protein both actively invade through the Matrigel (Figure 1d , Supplementary Figure S1B ). However, Sema5A-Fc treatment inhibits cell invasion by 20-40% as compared with Fc control in all cell lines examined, among which U87-MG cells displayed the most drastic response in a dose-dependent manner (Supplementary Figure S1C) . As plexin-B3 is the known functional receptor for Sema5A , its involvement in Sema5A-induced inhibition of glioma cell invasion was tested by downregulating the endogenous expression using RNA interference (RNAi). U87-MG cells subjected to plexin-B3 small-interfering RNA (siRNA) treatment resulted in 480% reduction in expression of the protein 48 h after transfection, whereas control siRNA and mock transfection showed no effect ( Figure 1e ). These siRNAs were also confirmed to have no effect on the expression of a closely related family member plexin-B1 (data not shown). When these cells were subjected to Sema5A stimulation, the inhibition of cell invasion was almost entirely abolished ( Figure 1f ). As glioma cells expressing siRNA control or mock transfected still showed marked inhibition in invasion by Sema5A-Fc as in their wild-type counterparts, these results suggest that Sema5A inhibits human glioma cell invasion through its receptor plexin-B3, further supporting our former observations in rat glioma cells (Li and Lee, 2010) .
Sema5A and plexin-B3 inhibit glioma cell invasion through Rac1 inactivation Semaphorins and plexins are known to control cell motility by regulating cytoskeletal dynamics through GTPases, such as Rac1 and RhoA (Driessens et al., 2001 (Driessens et al., , 2002 Hu et al., 2001; Barberis et al., 2004) . To assess the potential contributions of GTPases to Sema5A-induced inhibition of glioma cell motility, the levels of active Rac1/Cdc42 and RhoA in glioma cells were measured by glutathione S-transferase-PAK1-binding domain (GST-PBD) and GST-rhotekin pulldown assays, respectively. Treatment of glioma cells with Sema5A-Fc led to a remarkable reduction of Rac1-GTP to 33% of that in non-stimulated and Fc-treated cells ( Figure 2 ). The downregulation of active Rac1 by Sema5A is dependent on plexin-B3 as shown by the lack of effect when endogenous expression of plexin-B3 in glioma cells was silenced (Figure 2 ). No significant change in the levels of active Cdc42 and RhoA was detected when glioma cells were challenged with Sema5A-Fc under the same conditions (data not shown). Enhanced cell invasion in gliomas and many other types of cancer is known to be associated with aberrant activation of Rac1 (Crowe, 2004; Iwadate et al., 2004; Nakada et al., 2006) , and can be impeded by Rac1 suppression McDonough et al., 2005) . Therefore, significant reduction of Rac1-GTP level by Sema5A can contribute to the inhibition of glioma cell motility. To test this hypothesis, glioma cells were transfected with constitutively active Rac1 and subjected to Transwell Matrigel invasion assays in the presence of Sema5A-Fc or the Fc control protein.
Although Sema5A still imposed a similar degree of inhibition of cell invasion in the vector control, the effect was significantly attenuated upon forced expression of Figure 2 Sema5A and plexin-B3 inhibit Rac1 activation in glioma cells. Human glioma cells non-stimulated (NS), treated with Sema5A-Fc (5A) or Fc were subjected to a GST-PBD pulldown assay to measure the level of Rac1-GTP. In western blot analysis using anti-Rac1 antibody, band intensity of active Rac1 (upper panel) was normalized against that of total Rac1 (lower panel) in each sample. Results from the Sema5A-Fc and the Fc groups were expressed as a percentage to the non-stimulated reference as summarized in the bar graph. Rac1-GTP levels in glioma cells transfected with plexin-B3 siRNA or siRNA control were similarly measured. ***Po0.001 vs Fc control.
Sema5A and plexin-B3 in glioma progression X Li et al active Rac1 (Supplementary Figure S1D) . These findings corroborate that the blockade of glioma cell motility by Sema5A and plexin-B3 is mediated through Rac1 inactivation.
Plexin-B3 interacts with the actin-binding protein fascin-1 Next, the signaling pathways mediated by plexin-B3 were characterized. A yeast two-hybrid screening of mouse brain cDNA library revealed fascin-1, an actinbinding and bundling protein, as an interacting partner of the cytoplasmic domain of plexin-B3 (plexin-B3CD).
To confirm the interaction between plexin-B3CD and fascin-1, they were expressed as GST-fusion and maltose-binding protein (MBP)-fusion proteins, respectively, and subjected to GST-pulldown assays. Fascin-1 was found to co-precipitate with GST-plexin-B3CD but not with GST protein alone (Figure 3a) . Their interaction in the mammalian brain was also similarly verified with in vitro binding assay by incubating mouse total brain lysates with GST-plexin-B3CD. Western blot analysis revealed the presence of fascin-1 in GSTplexin-B3CD but not in the GST precipitate ( Figure 3b) . Notably, fascin-1 expression has been confirmed in all four human glioma cell lines examined in this study by immunoblotting (Supplementary Figure  S2) . To verify the interaction of endogenous plexin-B3 and fascin-1, human glioma cell lysates were subjected to immunoprecipitation (IP) assays using anti-plexin-B3CD antibody (or anti-fascin-1 in reciprocal IP). As shown in Figure 3c , plexin-B3 and fascin-1 were co-immunoprecipitated in both IP assays. Fascin-1 is known to modulate the organization of actin cytoskeleton and has been implicated in the regulation of cell adhesion, cell motility and cancer cell invasion (Kureishy et al., 2002; Adams, 2004) . The present finding suggests fascin-1 as a potential effector of plexin-B3 to mediate the signal of Sema5A in glioma cells.
Sema5A and plexin-B3 remodel F-actin cytoskeleton and induce fascin-1 translocation in glioma cells To study the role of fascin-1 in plexin-B3 signaling, the distribution of fascin-1 and the organization of F-actin cytoskeleton during Sema5A-induced inhibition of cell migration and invasion were examined. Immunofluorescence staining of non-stimulated human glioma cells revealed predominant localization of fascin-1 to the cortical region of the cytosol (Figure 4aii ), although signal can also be detected in extended processes in the cells (Figure 4aii , arrowheads). Phalloidin stain of these cells showed highly organized F-actin stress fibers throughout the cytosol (Figure 4ai , arrows), which partially colocalize with fascin-1 (Figure 4aiii ). Interestingly, stimulation of glioma cells with Sema5A-Fc resulted in an extensive disassembly of F-actin stress fibers as early as 15 min after treatment (Figure 4bi ). . However, by 24 h after treatment, cells partially resumed epithelial-like morphology, although cell shrinkage and disruption of actin stress fibers were still notable ( Figure 4g ). These cytological changes could be attributable to Sema5A because no change was observed in cells treated with Fc control throughout the course of study .
To confirm the involvement of plexin-B3 in mediating the cytological effects of Sema5A, glioma cells subjected to plexin-B3 gene silencing by RNAi were similarly stimulated with Sema5A-Fc. Fascin-1 distribution and F-actin network remained unchanged in 490% of cells in which the endogenous plexin-B3 expression was Sema5A and plexin-B3 in glioma progression X Li et al downregulated ( Figure 4l ), whereas cells treated with siRNA control displayed the same set of Sema5A-induced changes as in wild-type cells (Figure 4o ). In summary, Sema5A and plexin-B3 interaction in glioma cells results in the disassembly of F-actin stress fibers, cellular collapse and ramification of processes, which are accompanied by a concerted redistribution of F-actin and fascin-1 from the cytosol to protrusions. Intriguingly, Sema5A fails to induce these changes in rat C6 glioma cells, which endogenously express plexin-B3 but are devoid of fascin-1 (Li and Lee, 2010) .
Sema5A regulates the phosphorylation states of fascin-1 through plexin-B3
The incidental change in localization of F-actin and fascin-1 from the cytosol to newly formed protrusions in glioma cells upon Sema5A stimulation raises the possibility that their associations are co-regulated in these two sites. Former studies have shown that the actin-binding and bundling activities of fascin-1 are inhibited by phosphorylation at Ser-39 by protein kinase C (PKC) (Anilkumar et al., 2003) . Therefore, we ask whether the phosphorylation states of fascin-1 are subjected to modulation by Sema5A. , and 24 h (panels g and j), the distribution of F-actin (red, i) and fascin-1 (green, ii) in cells was detected using TRITC-conjugated phalloidin and anti-fascin-1 antibody, respectively. The nucleus was stained with DAPI (blue). Merged photos show colocalization of F-actin and fascin-1 (aiii-giii, h-j). (k-p) Similarly, U87-MG cells transfected with plexin-B3 siRNA (panels k-m) or control siRNA (panels n-p) were subjected to Sema5A-Fc stimulation. Colocalization of F-actin and fascin-1 in the cells at various time points indicated in the figures was shown in the merged photos. Arrows and arrowheads refer to features indicated in text. Inset in ciii is a magnified view of the boxed area. Scale bar, 10 mm.
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Sema5A-induced fascin-1 phosphorylation and actin network remodeling are mediated by PKC As PKC is known to regulate the interaction of fascin-1 with F-actin through phosphorylation, it represents a promising candidate for Sema5A-induced transient phosphorylation of fascin-1. To test this, we examined the activation state of PKC upon Sema5A stimulation. Glioma cells challenged with Sema5A-Fc were found to show a significant elevation in the level of phosphorylated PKC as compared with Fc treatment (Figure 6a ). The activation of PKC was abolished in cells pretreated with a PKCa inhibitor Go6976 (Figure 6a ). We next asked whether PKC activation by Sema5A could have contributed to the phosphorylation of fascin-1. To this end, glioma cells were subjected to Go6976 treatment for 30 min before Sema5A-Fc challenge. As shown in Figure 6b , the exposure to PKC inhibitor prevented the induction of fascin-1 phosphorylation by Sema5A-Fc. Cells pretreated with the vehicle dimethyl sulfoxide alone still responded to Sema5A stimulation by showing an increase in the level of phosphorylated fascin-1 (Figure 6b ). Having confirmed PKC as the kinase that phosphorylates fascin-1, its effects on Sema5A-induced alterations of the actin cytoskeletal network and fascin-1 localization in glioma cells were investigated. Interestingly, cells pretreated with Go6976 showed no major disassembly of actin stress fibers throughout the course of Sema5A-Fc stimulation ( Figure 6c ). Translocation of fascin-1 to membrane and protrusions was also insignificant, although a modest degree of aggregation of fascin-1 immunostaining was observed at 3 and 6 h ( Figure 6c , arrows). Furthermore, no cellular collapse and ramification of protrusions were found. In contrast, cells pretreated with the vehicle dimethyl sulfoxide alone responded to Sema5A-Fc stimulation in the same way as did wild-type U87-MG glioma cells (Figure 6c ). Taken together, these findings indicate that PKC activation is involved in both the phosphorylation and the translocation of fascin-1, and the concomitant remodeling of actin cytoskeleton induced by Sema5A.
Fascin-1 is required for Sema5A-induced morphological changes in glioma cells Next, we asked specifically whether fascin-1 is involved in Sema5A-induced morphological changes in glioma cells by manipulating its expression level. As shown in Figure 7a , fascin-1 expression in U87-MG cells was reduced by 490% after siRNA transfection for 72 h. Notably, downregulation of fascin-1 led to a significant disassembly of F-actin stress fibers as revealed by phalloidin stain (Figure 7b ), which is reminiscent of the early effect of Sema5A-Fc in disrupting the actin cytoskeleton in wild-type U87-MG cells (Figure 4b ). Nonetheless, stimulating these cells with Sema5A-Fc failed to induce significant ramification of cell protrusions as in glioma cells expressing normal levels of fascin-1 (Figures 4c-f vs 7b, Figure 7d ). By contrast, forced expression of enhanced green fluorescent proteintagged fascin-1 in glioma cells was found to promote the formation of cell protrusions (Figure 7c ). Challenging these cells with Sema5A-Fc induced an accelerated cell collapse response and ramification of processes as early as 15 min, which in wild-type cells would only appear after 1 h of stimulation (Figures 4d vs 7c) . Stimulation of fascin-1-overexpressing cells for 3 h resulted in the formation of significantly longer protrusions than Sema5A and plexin-B3 in glioma progression X Li et al mock-transfected control (Figures 7c and d) . The heightened responses subsided by 6 h, during which no significant difference in cell morphology was observed as compared with the mock control. Therefore, these findings suggest the importance of fascin-1 in mediating Sema5A-induced remodeling of actin cytoskeleton and promotion of process outgrowth in glioma cells.
Sema5A and plexin-B3 disrupt focal adhesions in glioma cells As Sema5A induces an extensive disruption of actin fibers in glioma cells, an alteration in cell adhesion is expected. Vinculin is one of the components in focal adhesion complexes that anchor F-actin to adhesion points on membrane. In epithelial cells, fascin-1 activities have been shown to regulate the dynamics of vinculin-positive focal adhesions (Yamashiro et al., 1998) . Therefore, we examined the effect of Sema5A stimulation on focal adhesions by immunofluorescence staining for vinculin. In non-stimulated cells, F-actin is anchored to the cell membrane through vinculinpositive focal adhesions (Supplementary Figure S3Aiii , arrowheads). However, Sema5A stimulation for 15 min resulted in a drastic reduction in vinculin signal in focal adhesions (Supplementary Figure S3B) , which virtually disappeared at 30 min (Supplementary Figures S3C and G) . Importantly, the disruption of focal adhesions temporally coincides with F-actin disassembly described above. Glioma cells subjected to Fc protein treatment for 30 min showed no observable effects on vinculin and F-actin (Supplementary Figure S3D) . The negative regulation of vinculin by Sema5A was abolished when endogenous plexin-B3 expression in glioma cells was silenced by RNAi ( Supplementary Figures S3E and G) , but persisted in the siRNA control ( Supplementary  Figures S3F and G) . These findings suggest that Sema5A disrupts focal adhesions through its receptor plexin-B3, which is consistent with the concomitant loss of actin stress fibers in glioma cells.
Sema5A induces astrocytic differentiation and GFAP expression in glioma cells
Sema5A was found to induce not only remodeling of F-actin cytoskeleton but also morphological changes in glioma cells. However, similar to other glioma cell lines U87-MG cells are morphologically heterogeneous, with the majority being epithelial-like and a minor population of process-bearing slender cells. Therefore, we quantified alterations in U87-MG morphology upon Sema5A-Fc or Fc stimulation according to five different Sema5A and plexin-B3 in glioma progression X Li et al Sema5A and plexin-B3 in glioma progression X Li et al pre-defined criteria (class I-V as depicted in Figure 8a ). In the presence of Fc protein, the majority of cells (B65%) adopted epithelial morphology (class I), and only 25% were slender cells with multiple protrusions (class II-IV). However, upon Sema5A stimulation for the same duration 475% of cells showed multiple protrusions and o20% were of epithelial morphology (Figure 8a) . Notably, 25% of cells produced 43 protrusions with length 450 mm (class IV) when challenged with Sema5A-Fc but none was observed in the Fc control. As stated above, intense signals of F-actin and fascin-1 were detected in these long processes and they showed significant degree of colocalization (Figures 4diii-fiii, arrowheads) . As the morphology of Sema5A-stimulated cells resembles that of astrocytes, we asked whether they express the astrocytic marker glial fibrillary acidic protein (GFAP). In agreement with former studies, GFAP expression was undetectable in wild-type U87-MG cells by reverse transcriptase-PCR and western blot analysis (Figures 8b and d) (Feldkamp et al., 1999; Brun et al., 2009) . Although GFAP remained undetectable in cells treated with Fc control, its expression was first detected after 2 h of Sema5A-Fc stimulation (Figure 8b ). Immunofluorescence staining revealed localization of GFAP both in the soma and in the processes of U87-MG cells (Figure 8cii ). The induction of GFAP expression was abolished by silencing endogenous plexin-B3 expression (Figures 8b and ciii) but remained in the siRNA control (Figure 8civ ), suggesting its dependence on plexin-B3. These findings show that Sema5A induces GFAP protein expression, and the process involves transcriptional regulation. To evaluate the contribution of Sema5A-induced expression of GFAP to morphological differentiation of U87-MG cells, its expression was silenced by RNAi. As shown in Figure 8d , the induction of GFAP expression in cells transfected with GFAP siRNA is significantly suppressed, whereas scrambled siRNA control Figure 8 Sema5A induces morphological differentiation and GFAP expression in human glioma cells. (a) Glioma cells subjected to Sema5A-Fc or Fc stimulation for 6 h were stained with TRITCconjugated phalloidin to reveal the actin cytoskeleton. Cells were categorized according to their morphologies, the number and length of protrusions as defined in the figure (class I-V). Quantification was then performed on a minimum of 300 cells per round. The results in triplicate were expressed as a percentage relative to the total number of cells counted, and summarized in the bar graph. *Po0.05, **Po0.01, ***Po0.001 vs Fc control. Scale bar, 10 mm. (b) Expression of GFAP in U87-MG cells that were non-stimulated (lane 1), or challenged with Sema5A-Fc for 1, 2 and 3 h (lanes 2-4) were examined by RT-PCR. Reaction without reverse transcription served as control (lane 5). Lane 6 is cells in which plexin-B3 expression was silenced before Sema5A stimulation for 3 h. (c) Sema5A induces GFAP expression in glioma cells through plexin-B3. U87-MG cells plated on coverslips pre-coated with fibronectin were subjected to Fc (i) or Sema5A-Fc (ii) stimulation for 6 h. Cells were then incubated with anti-GFAP antibody and detected with Alexa546-conjugated secondary antibody. The nucleus was stained with DAPI. Cells transfected with plexin-B3 siRNA (iii) or scrambled siRNA control (iv) were similarly treated and probed for GFAP expression. Scale bar, 10 mm. (d) GFAP expressions in untransfected (UT) U87-MG cells non-stimulated, stimulated with Fc or Sema5A-Fc for 6 h were examined by western blot. The same analysis was performed on cells transfected with GFAP-specific siRNAs or siRNAs of scrambled sequences before Sema5A-Fc stimulation. Equal loading of protein across samples was verified by detection of GAPDH signal. (e) U87-MG cells transfected with GFAP siRNAs or siRNA control were challenged with Sema5A-Fc. Cells that fall into the five different classes of morphologies as defined above were counted. The results in triplicate were expressed as a percentage relative to the total number of cells, and summarized in the bar graph. **Po0.01, ***Po0.001 vs Sema5A þ siRNA control.
Sema5A and plexin-B3 in glioma progression X Li et al is ineffective. When cells transfected with siRNA control were challenged with Sema5A-Fc, 480% of cells showed multiple protrusions and o15% were of epithelial morphology (Figure 8e ), in agreement with the responses of wild-type U87-MG cells described above. However, when GFAP expression was silenced, the majority of cells exhibited type II bipolar morphology upon Sema5A-Fc stimulation (46 vs 30% in siRNA control). Notably, only o5% of cells progressed to the advanced differentiation morphology (type IV), as compared with 20% in the siRNA control group (Figure 8e ). These findings suggest that the induction of GFAP expression contributes to the ramification of processes in glioma cells subjected to Sema5A stimulation.
Sema5A expression is downregulated in advanced grades of astrocytomas High-grade gliomas are highly infiltrative and are often associated with recurrence after tumor resection. As Sema5A and plexin-B3 are found to counteract glioma cell invasion in this study, it is of interest to understand the clinical relevance of these findings. As a first step to address this issue, the expression of Sema5A and plexin-B3 in various grades of human astrocytomas was examined. Intriguingly, although all specimens were found to be positive for both Sema5A and plexin-B3 protein (Figure 9a and data not shown), Sema5A protein expression is markedly reduced in grade III anaplastic astrocytomas to 57% of that in normal brain samples. The level was further reduced to 21% in the most advanced grade IV glioblastoma multiforme (Figure 9a ). The decline of Sema5A expression towards high-grade gliomas implicates a compromise in its suppressive effects in glioma cell motility, potentially contributing to the high invasiveness of these cancer cells. This notion is supported by an increase in invasiveness of U87-MG cells when endogenous Sema5A expression is silenced by siRNA (Figure 9b) . Notably, fascin-1 expression was detected in all the clinical specimens analyzed, and is often upregulated in glioblastomas.
Discussion
Although accumulating evidence has demonstrated a correlation between semaphorin expression and glioma progression (Correa et al., 2001; Rieger et al., 2003; Rich et al., 2005) , studies of the expression of plexins and the role of semaphorin-plexin interactions in gliomas remain scanty (Rieger et al., 2003; Bagci et al., 2009; Nasarre et al., 2009; Coma et al., 2010) . Here, we show that plexin-B3 is expressed in human glioma cells, which upon activation by its ligand Sema5A inhibits cell motility, triggers cell collapse and promotes ramification of processes. Concomitant with these changes are the inactivation of Rac1 GTPase, remodeling of F-actin cytoskeleton, disruption of focal adhesions and re-expression of GFAP (Figure 10 ). This represents Figure 9 Analysis of Sema5A and fascin-1 expression in human glioma specimens. (a) Crude protein extracts isolated from human astrocytomas of various grades as defined by the WHO classification were subjected to western blot analysis using anti-Sema5A or anti-fascin-1 antibody. Equal loading of protein across samples was verified by probing the blot with anti-GAPDH antibody. A total of 22 specimens (normal: 2; grade II: 4; grade III: 6; grade IV: 10) were analyzed. The band intensity of Sema5A was normalized against that of GAPDH in each sample, and the results were summarized in the bar chart. U87-MG and C6 glioma cell lines were also included in the analysis. (b) The invasive properties of U87-MG cells mock transfected, transfected with scrambled siRNA control or Sema5A siRNA were examined by Matrigel Transwell assays. Invaded cells were counted and normalized against mock-transfected control. ***Po0.001 vs mock control.
Sema5A and plexin-B3 in glioma progression X Li et al novel functions of transmembrane semaphorin 5A and plexin-B3 in alteration of glioma cell characteristics. In this study, Sema5A was found to induce a significant reduction in the level of active Rac1 in glioma cells. Rac1 is known to have pivotal roles in cell migration by organizing the actin cytoskeleton into lamellipodia, which generate locomotive force at the leading edge. Furthermore, Rac1 promotes tumor cell invasion through the activation of matrix metalloproteinases such as matrix metalloproteinase-2 and matrix metalloproteinase-9, which are strongly upregulated in gliomas and contribute to cell invasion (Deryugina et al., 1997; Wick et al., 2001; Zhuge and Xu, 2001 ). Numerous reports have in fact demonstrated the association of glioma invasiveness with elevated levels of Rac1-GTP (Iwadate et al., 2004; Nakada et al., 2006) , which upon inactivation can impede glioma cell migration and invasion McDonough et al., 2005) . Therefore, the inactivation of Rac1 by Sema5A and plexin-B3 can contribute to the inhibition of glioma cell motility. This is supported by the disinhibition of Sema5A-induced impediment of cell invasion upon forced expression of constitutively active Rac1 in glioma cells. Our recent study has revealed the role of RhoGDIa in mediating the inactivation of Rac1 by Sema5A and plexin-B3 (Li and Lee, 2010) .
Accumulating evidence suggests that semaphorins and plexins regulate cell motility through the modulation of integrin-mediated signaling and adhesion (Serini et al., 2003; Barberis et al., 2004; Walzer et al., 2005; Oinuma et al., 2006) . A robust disruption of vinculinpositive focal adhesions by Sema5A and plexin-B3 is indeed demonstrated in this study. Incidentally, Sema4D was found to inhibit cell migration in fibroblasts and neuroblastomas through negative regulation of integrin functions Oinuma et al., 2006) . Delineation of the signaling pathways revealed that Sema4D triggers the endogenous GTPase-activating activity of plexin-B1 towards R-Ras by promoting Rnd1 binding to the cytoplasmic domain (Oinuma et al., 2004) , leading to inactivation of R-Ras and phosphatidylinositol 3-kinase activity, thereby compromising cell adhesion and migration functions of integrin (Oinuma et al., 2006) . As the Rnd1-binding motif and the two Ras-GTPase activating activity domains are highly conserved between plexin-B1 and plexin-B3, further experiments to verify the engagement of this pathway in the suppression of integrin functions in glioma cells challenged with Sema5A are warranted. Vinculin is an important component in integrin-dependent focal adhesion complexes that anchor F-actin to the plasma membrane. The induction of an extensive disruption of vinculin-positive focal adhesions and actin stress fibers by Sema5A corroborates former studies that showed the association between a loss of vinculin and reduced stress fibers (Ridley and Hall, 1992) , which are phenomena correlated with compromised tumor cell motility and invasiveness (Wong et al., 2008) . Although it is not clear whether a consequential correlation exists between these two events, their concerted regulations are known to be essential for cell motility: F-actin fibers provides the driving force for cell movement, whereas focal adhesions are molecular clutches that couple the dynamic cytoskeleton with the substratum to provide traction force as cells migrate (Webb et al., 2003) . Deregulation of these two components by Sema5A will contribute to the inhibition of glioma cell motility.
A peculiar effect of Sema5A on U87-MG glioma cells is the induction of prominent changes in cell morphology, ranging from cell collapse to ramification of processes, which are concomitant with remodeling of the actin network. We provide evidence that Sema5A temporally regulates phosphorylation states of the actinmodifying protein fascin-1 through PKC. Blockage of fascin-1 phosphorylation or silencing of its expression is sufficient to abolish the cytoskeletal changes and process ramifications induced by Sema5A, whereas overexpression of fascin-1 accelerates morphological differentiation. Notably, Sema5A stimulation of C6 glioma cells, which endogenously express plexin-B3 but are deficient in fascin-1 fails to promote process outgrowth (Li and Lee, 2010) . These findings suggest the importance of fascin-1 in mediating Sema5A-induced remodeling of actin cytoskeleton and promotion of process outgrowth in glioma cells. We hypothesize that transient PKCmediated phosphorylation of fascin-1 in the first 15 min of Sema5A stimulation reduces its actin-binding and bundling activity, contributing in part to the disruption of F-actin stress fibers observed. This also facilitates subsequent translocation of fascin-1 to F-actin-rich protrusions, which temporally coincides with the subsiding of fascin phosphorylation as reported above, hence promoting cross-linking of actin fibers in the extending cell protrusions. In addition to fascin, we provide evidence that the concomitant induction of GFAP expression by Sema5A also contributes to the morphological differentiation phenotype of glioma cells. Blockade of GFAP re-expression by RNAi results in a precipitous drop in the percentage of cells that bear multiple long protrusions (type IV), and the majority of cells progress only to the bipolar stage (type II) in response to Sema5A-Fc stimulation. As silencing fascin-1 expression abolishes Sema5A-induced process outgrowth altogether, these findings suggest the complementary functions of fascin-1 and GFAP in early (bipolar) and late (process ramifications) phases of morphological differentiation of glioma cells induced by Sema5A, respectively. Commonly used as an astrocytic marker, GFAP is an intermediate filament protein implicated in the differentiation of astrocytes, although the underlying mechanism remains unclear. The polymerization of GFAP is known to stabilize the glial filament network (Inagaki et al., 1990) , which may serve to impair cytoplasmic plasticity required for cell motility (Duffy et al., 1982) . Intriguingly, a recent report has revealed the association between fascin-1 and GFAP in human astrocytoma cells (Mondal et al., 2009) . This raises the possibility of potential crosstalk between the intermediate filament and the actin microfilament cytoskeletal networks. Further experiments are required to clarify the role of GFAP and fascin-1 in this context. The induction of prominent ramification of processes and the re-expression of the astrocytic marker GFAP suggests an astrocytic differentiation of glioma cells. Increasing malignancy of gliomas is always accompanied by a reduction or complete loss of GFAP expression (Deck et al., 1978; Rutka et al., 1997) . Forced expression of GFAP in glioma cells has been shown to promote the extension of cell processes, inhibit cell motility, proliferation and tumorigenicity (Rutka and Smith, 1993; Elobeid et al., 2000; Murakami et al., 2001) . Conversely, downregulation of endogenous GFAP expression in low-grade human gliomas by RNAi promotes the transformation of cells to epithelioid morphology devoid of glial processes, and an increase in cell invasion (Rutka et al., 1994) . Therefore, the promotion of astrocytic differentiation in glioma cells by Sema5A points to its potential tumor-suppressor function. The mechanism whereby Sema5A induces GFAP gene expression is not clear. Notably, a recent report has shown that GFAP expression in high-grade glioblastomas is suppressed through epigenetic regulation at the promoter level (Restrepo et al., 2010) .
In summary, this study demonstrated the effect of Sema5A and plexin-B3 in counteracting cell motility, while promoting cell collapse and extensive process ramifications in human glioma cells through various pathways (summarized in Figure 10 ). The marked decline in Sema5A protein expression in clinical specimens of high-grade human gliomas reported in this study would compromise these effects, hence contributing to the highly infiltrative and anaplastic characteristics of glioblastomas. In fact, silencing Sema5A expression in U87-MG cells, or low level of endogenous Sema5A in rat C6 cells (vs U87-MG) correlate with enhanced invasiveness in glioma cells. In line with this, a recent report has also demonstrated a significant downregulation of the Sema5A transcript and protein in nonsmall cell lung carcinoma, which correlates with poor survival of patients (Lu et al., 2010) . Consistent with our working hypothesis but from a different perspective, a recent study has reported a novel plexin-B3 missense mutation in human pancreatic ductal adenocarcinomas that prevents its interaction with Sema5A, hence impairing their signaling and contributing to tumor progression (Balakrishnan et al., 2009) . These findings point to the potential tumor-suppressor function of Sema5A and plexin-B3. Nonetheless, heightened expression of Sema5A and plexin-B3 has been documented in pancreatic cancer (Sadanandam et al., 2010) and gastric carcinoma (Pan et al., 2009 (Pan et al., , 2010 . Ectopic expression of Sema5A in a pancreatic carcinoma cell line enhances tumorigenesis (Sadanandam et al., 2010) , whereas silencing Sema5A in a gastric cancer cell line suppresses anchorage-independent growth (Pan et al., 2010) . In fact, contrasting functions of Sema5A is not unprecedented. Sema5A was found to be bi-functional in the nervous system by serving as both inhibitory and attractive cues towards developing axons (Oster et al., 2003; Goldberg et al., 2004; Kantor et al., 2004; Hilario et al., 2009) . Evidence points to the repulsive and permissive functions of the sema domain and thrombospondin repeats of Sema5A, respectively, by engaging different receptor complexes (Kantor et al., 2004; Hilario et al., 2009) . Furthermore, opposing effects of Sema5A may also be mediated through the association of plexin-B3 with various co-receptors. Plexin-B1 and plexin-B3 were shown to bind both c-Met protooncogene and ErbB2 Swiercz et al., 2004) . Intriguingly, stimulation of plexin-B1 with Sema4D can induce pro-or anti-migratory effects in breast carcinoma cells through interaction with ErbB-2 or c-Met in the cells, respectively (Swiercz et al., 2008) . As U87-MG cells are known to express both ErbB2 and c-Met, it will be interesting to study whether Sema5A triggers differential interaction of plexin-B3 with these co-receptors.
Gliomas are notorious for their highly infiltrative properties that lead to frequent recurrence even after radical surgical resection. The present findings of Sema5A and plexin-B3 in inhibiting invasion and inducing astrocytic differentiation in glioma cells provide the impetus for further exploration of their mechanistic actions and potential clinical applications in counteracting this highly aggressive form of cancer.
Materials and methods

Antibodies and cell lines
Antibodies directed against GST, MBP and fascin-1 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and human IgG-Fc were obtained from Chemicon International (Billerica, MA, USA). Rac1 antibody was obtained from BD Transduction Laboratory (Franklin Lakes, NJ, USA). GFAP antibodies were purchased from Dako (Glostrup, Denmark) and Cell Signaling Technology (Danvers, MA, USA). Anti-vinculin and anti-human IgG-Fc peroxidase-conjugated antibodies were obtained from Sigma Sema5A and plexin-B3 in glioma progression X Li et al (St Louis, MO, USA). Horseradish peroxidase-conjugated and Alexa fluorophore-conjugated secondary antibodies were purchased from Pierce (Rockford, IL, USA) and Invitrogen (Carlsbad, CA, USA), respectively. Anti-plexin-B3CD polyclonal antibody against the cytoplasmic domain of plexin-B3 (AA 1635-1654) was generated and affinity-purified in our laboratory. Human U87-MG glioma cells were obtained from the ATCC (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% penicillin (100 IU/ml)/streptomycin (100 mg/ml). Human U373-MG, A172 and MOG-G-CCM (from ECACC, Salisbury, Wiltshire, UK) glioma cells were cultured in DMEM/F-12 (1:1) (Hyclone, Rockford, IL, USA) with 10% fetal bovine serum and 1% penicillin/streptomycin. All cells were grown at 37 1C in a humidified atmosphere of 5% CO 2 .
Recombinant protein expression
To express fascin-1 as a MBP-fusion protein, full-length cDNA of fascin-1 was amplified by reverse transcriptase-PCR from adult mouse brain RNA and cloned into pMALC2 vector through BamHI and HindIII sites. The cytoplasmic domain of mouse plexin-B3 was expressed as a GST-fusion protein by cloning the PCR-amplified cDNA fragment into the EcoRI and BamHI sites of pGEX-KG vector. Each of these expression constructs was transformed into the BL21 strain of Escherichia coli, and the expression of recombinant proteins was induced by 0.5-1 mM of isopropyl b-D-thiogalactopyranoside. Bacteria were subjected to sonication and the GST-or MBP-fusion proteins in soluble fraction of the resulting bacterial lysates were purified with glutathione (GSH)-Sepharose 4B beads (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) or amylose resin (New England Biolabs, Ipswich, MA, USA), respectively, following manufacturers' instructions. Correct expression of these proteins was confirmed with Coomassie blue staining and western blot.
GST-pulldown assays
Purified MBP or MBP-fascin-1 proteins was incubated with 20 ml of GST or GST-plexin-B3CD protein pre-bound to Sepharose 4B beads in a binding buffer (20 mM Tris-Cl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) containing 0.1% Triton X-100, 1 mM PMSF and 1 Â protease inhibitor cocktail (Roche, Mannheim, Germany) for 2 h. Beads were collected by centrifugation, washed 3 times with 1 Â phosphate-buffered saline (PBS) and eluted in SDS sample buffer, followed by SDS-PAGE and western blot analysis. To verify the yeast twohybrid screening results in mammalian cells, mouse brain lysates were similarly subjected to pulldown assay with GSTplexin-B3CD. In brief, postnatal day (P) 7 mouse brain was homogenized in 1 ml binding buffer supplemented with 0.1% Triton X-100, 1 mM PMSF and 1 Â protease inhibitor cocktail. After lysis for 30 min at 4 1C with gentle shaking, brain lysates were pre-cleared with 30 ml of GSH-bound Sepharose beads, followed by overnight incubation with 30 ml of GST or GSTplexin-B3CD pre-bound to Sepharose beads at 4 1C with gentle agitation. Beads were then washed three times with binding buffer. Proteins were eluted in sample buffer and subjected to western blot analysis using anti-fascin-1 antibody and horseradish peroxidase-conjugated secondary antibody, followed by chemiluminescence detection with X-ray film.
Reverse transcriptase-PCR Total RNA isolated from cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) was reverse transcribed by Superscript II reverse transcriptase (Invitrogen) and oligo-dT primer, followed by PCR amplifications using the following primer pairs: human plexin-B3 (5 0 -TCAACATTTCCGA GGCCTGC-3 0 and 5 0 -TGCCTGGTGGCTGGCTCTTA-3 0 ), human GFAP (5 0 -CGACAGCAGGTCCATGTG-3 0 and 5 0 -GTCTGCACGGGAATGGTG-3 0 ) and human GAPDH (5 0 -TTTGCGTCGCCAGCCGAGC-3 0 and 5 0 -TTGGCAGCG CCAGTAGAGG-3 0 ). PCR products were then analyzed by agarose gel electrophoresis.
Production of soluble Sema5A-Fc and Fc proteins The expression construct pEX/Sema5AED-Fc, which encompasses a fusion cDNA between the extracellular domain of Sema5A and the Fc region of human IgG (Sema5A-Fc) was transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. An IgG-Fc expression plasmid serves as Fc control. Transfected cells were allowed to recover in DMEM containing 10% fetal bovine serum for 20 h before incubation in serum-free DMEM for 2 days. Conditioned medium containing Sema5A-Fc or Fc was purified and concentrated using Centricon column (Millipore, Billerica, MA, USA), followed by western blot analysis using anti-human IgG-Fc antibodies. For all functional studies, Sema5A-Fc and Fc proteins were pretreated with anti-human IgG-Fc antibodies at a concentration of 7.5 mg/ml for multimerization.
Glioma cell migration and invasion assays Glioma cell migration was analyzed by a wound-healing assay. In brief, cells were seeded into 6-well culture dishes at a density of 4 Â 10 5 cells per well. Physical 'scratch wounds' were created through the cell layer using a p-20 ml pipette tip to stimulate cell migration. After a brief wash in DMEM to remove dislodged cells, cells were incubated in conditioned medium containing Sema5A-Fc or Fc protein for 24 h. 'Wound closure' was monitored and documented by photomicrography for post hoc quantification of migrated cells. Glioma cell invasion was analyzed by in vitro transfilter Matrigel assay. In brief, Transwell insert (8 mm pore size, Costar, Acton, MA, USA) was pretreated with Matrigel solution (1 mg/ml in DMEM, BD Bioscience, Franklin Lakes, NJ, USA) at 37 1C for 2 h. Overall, 2 Â 10 4 glioma cells in serum-free DMEM were plated into the Transwell insert and allowed to migrate and invade through Matrigel towards either Sema5A-Fc or Fc control protein in the lower chamber for 24 h. Cells that remained on the inner side of the membrane were removed with a cotton swab, and those that invaded through Matrigel to the outer side of the membrane were stained with 0.2% crystal violet in 0.9% NaCl containing 10% ethanol. Cells were photographed and the dye solubilized in 10% acetic acid to measure absorbance at 590 nm in a microplate reader.
Gene silencing
Glioma cells were transfected with siRNAs against human plexin-B3 (Plexin-B3 siRNA-1: 5 0 -ACAUGAGCCAAGCUG UCAUAG-3 0 ; siRNA-2: 5 0 -UAAAGAGCAUGGGUGUUG UCC-3 0 ; siRNA-3: 5 0 -UGUUGUUGUAGUCGGAGAAGU CGCC-3 0 ), or siRNAs in scrambled irrelevant sequence as control using Lipofectamine RNAiMAX according to the manufacturer's protocol (Invitrogen). In brief, cells were plated in antibiotics-free DMEM supplemented with 10% fetal bovine serum and 100 pmol siRNA in transfection reagent and cultured in a CO 2 incubator to reach 30-50% confluence in 24 h. The efficiency and specificity of plexin-B3 downregulation were assessed by western blot analysis 24-72 h after transfection.
Yeast two-hybrid library screening A GAL4-based two-hybrid interaction screen of adult mouse brain cDNA library (Clontech Laboratories, Mountain View, CA, USA) was performed using plexin-B3CD as a bait. In brief, yeast host AH109 harboring the bait expression plasmid pGBKT7/plexin-B3CD was mixed with Y187 yeast host pretransformed with the library according to the manufacturer's instructions. The transformants were screened on the quadruple dropout selection medium SD/-Ade/-His/-Leu/-Trp, and positive colonies were confirmed with X-a-Gal assay. Candidate plasmids were then isolated from the yeast, expanded in E. coli for sequence determination. Interactions between plexin-B3CD and the positive clones were confirmed by cotransforming the bait plasmid and the respective AD/library plasmids into the yeast host AH109, or by reciprocal mating of the yeast hosts AH109 and Y187 transformed with the AD/ library clone and the bait plasmid, respectively. The interaction was further verified in mammalian cells by pulldown and co-IP assays.
IP and immunoblotting
Glioma cells treated with Sema5A-Fc or Fc protein for 15 min were lysed in ice-cold RIPA buffer (50 mM Tris-Cl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF and 1% NP-40) containing 1 Â protease inhibitor cocktail. In all, 200 mg of pre-cleared lysates were incubated with 2 mg of antifascin-1 antibody overnight with agitation at 4 1C. In all, 20 ml of protein A agarose (Santa Cruz Biotechnology Inc.) was then added and incubated for another 2 h. The immunoprecipitates were washed thrice with PBS before western blot analysis using anti-phosphoserine/threonine or anti-fascin-1 antibodies. To confirm the interaction between plexin-B3 and fascin-1 in glioma, cell lysates were incubated with antibodies against plexin-B3 and the immunoprecipitate was detected with antifascin-1 antibody. Reciprocal IP was similarly performed using anti-fascin-1 antibody. Chemiluminescence immunoreactivity signals (Supersignal Western Pico, Pierce) were detected by autoradiography.
Immunocytochemistry
Glioma cells grown to 50% confluence on fibronectin-coated coverslips were stimulated with Sema5A-Fc or Fc protein.
At predetermined time points, cells were fixed in 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 in PBS for 2 min, followed by incubation in blocking buffer (2% bovine serum albumin in PBS) for 1 h at room temperature. Cells were then incubated with primary antibody for 1 h, followed by the corresponding Alexa fluorophoreconjugated secondary antibody. Actin filaments in cells were stained with tetramethyl rhodamine iso-thiocyanate (TRITC)-conjugated phalloidin (Sigma). Nucleus was stained with DAPI (4 0 ,6-diamidino-2-phenylindole). Finally, coverslips were mounted on microscopic slides using an antifade mounting agent (Aqua PolyMount, Polysciences, Warrington, PA, USA) and examined under confocal microscope (LSM 510, Zeiss, Jena, Germany).
RhoGTPase activation assays
Rac1-GTP levels in glioma cells were measured with a PBDpulldown assay previously described with modifications (Benard et al., 1999) . In brief, cells stimulated with Sema5A-Fc or Fc protein were extensively washed with PBS before lysis in RIPA buffer containing 1 Â protease inhibitor. In all, 100 mg of cleared lysates were pre-cleared with GSH-Sepharose beads in a binding buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 3 mM MgCl 2 ) containing 1 Â protease inhibitor cocktail for 15 min at 4 1C. It was then incubated for 45 min at 4 1C with GST-PBD-fusion protein coupled to GSH-Sepharose. Bound complexes were pelleted and washed twice in PBS. Equal amount of beads and total cell lysates were subjected to western blot analysis using anti-Rac1 and anti-Cdc42 antibodies. The intensity of immunoreactive signals was quantified with Quantity One software (Bio-Rad, Hercules, CA, USA).
Statistical analysis
All data are mean ± s.d. from at least three independent experiments. Differences between groups were analyzed by Student's t-test. Po0.05 is considered statistically significant.
